Fighting Cardiovascular Diseases with in silico Solutions
With more than 30 percent of all deaths attributed to cardiovascular diseases, the healthcare industry invests massively in disease prevention, treatment, and efforts to shorten the recovery period. Computational modeling and simulation (CM&S) of cardiovascular devices and their working environment — the human body and heart — is the most promising way to accelerate and amplify medical innovation while limiting the risk for the patients through in silico research, in silico testing, and in silico clinical trials. To see the full campaign, visit ansys.com.
